The COVID-19 pandemic has resulted in a tremendous increase in the burden on healthcare organizations across the globe. According to the WHO, as of September 29, 2020, there were 33,249,563 confirmed cases of COVID-19, including 1,000,040 deaths, with the highest number of deaths in the Americas, followed by Europe and Southeast Asia.



Currently, no effective treatment for COVID-19 is available in the form of vaccines or antiviral drugs, and patients are currently treated symptomatically. According to the WHO, there are 70 vaccine candidates under development, and three candidates are already being tested in human trials. At the forefront of the COVID-19 outbreak, many researchers worldwide are engaged in the viral research of SARS-CoV-2, the virus that causes COVID-19.



[ 212 Pages Report] The global live cell imaging market size is expected to reach USD 2.8 billion by 2025 from an estimated value of USD 1.8 billion in 2020, growing at a CAGR of 8.8% during the forecast period. growing adoption of high-content screening techniques in drug discovery and rising incidence of cancer primarily drives the market for live cell imaging.



The normalization of the global economy will slowly increase the demand for live cell imaging systems in non-COVID-related research activity labs, leading to market growth from the first quarter of 2021. Furthermore, players operating in the market are altering their strategies, for both long-term and short-term growth, by tapping the research market and developing innovative products to combat the pandemic.



The traditional method of toxicity and drug safety studies involves the screening of large libraries through high-throughput screening. This method is expensive, has a low success rate, and is resource- and time-consuming.



Download PDF Brochure @ https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=163914483



The use of HCS makes the drug development process more time- and cost-efficient. Owing to these factors, the adoption of high-content screening for toxicity studies is expected to increase during the forecast period. This, in turn, is expected to drive market growth as live cell imaging is used in HCS to identify meaningful information from complex systems such as in vitro, in vivo, and ex vivo systems.



Running live cell imaging experiments successfully can be a major challenge. The conditions under which cells are maintained under microscopes decide the success or failure of the experiment. Therefore, maintaining living cells on slides is the most crucial part of the experiment. The cells used in experiments should be in good condition and function normally under a microscope in the presence of synthetic fluorophores or fluorescent proteins.